Davita - West Hamilton Dialysis is a medicare approved dialysis facility center in Hamilton, Ohio and it has 17 dialysis stations. It is located in Butler county at 1532 Main Street, Hamilton, OH, 45013. You can reach out to the office of Davita - West Hamilton Dialysis at (513) 737-0158. This dialysis clinic is managed and/or owned by Davita. Davita - West Hamilton Dialysis has the following ownership type - Profit. It was first certified by medicare in June, 2015. The medicare id for this facility is 362826 and it accepts patients under medicare ESRD program.
Name | Davita - West Hamilton Dialysis |
---|---|
Location | 1532 Main Street, Hamilton, Ohio |
No. of Dialysis Stations | 17 |
Medicare ID | 362826 |
Managed By | Davita |
Ownership Type | Profit |
Late Shifts | No |
1532 Main Street, Hamilton, Ohio, 45013 | |
(513) 737-0158 | |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago
NPI Number | 1184038903 |
Organization Name | West Hamilton Dialysis |
Doing Business As | Borrego Dialysis Llc |
Address | 1532 Main St Hamilton, Ohio, 45013 |
Phone Number | (513) 737-0158 |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago
NPI Number | 1891109674 |
Organization Name | West Hamilton Home Training |
Doing Business As | American Dialysis Llc |
Address | 1532 Main St Ste B Hamilton, Ohio, 45013 |
Phone Number | (615) 341-6311 |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago
Dialysis patients with Hemoglobin data | 23 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 22 |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 63 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 496 |
Percentage of adult patients getting regular hemodialysis at the center | 94 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - West Hamilton Dialysis with elevated calcium levels.
Patients with hypercalcemia | 65 |
Hypercalcemia patient months | 509 |
Patients with Serumphosphor | 64 |
Patients with Serumphosphor less than 3.5 mg/dL | 8 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 35 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 38 |
Patient months included in arterial venous fistula and catheter summaries | 253 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 44 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 44 |
Hospitalization Rate in facility | 275.3 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 481.9 |
Hospitalization Rate: Lower Confidence Limit | 164.4 |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - West Hamilton Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 26.1 (As Expected) |
Readmission Rate: Upper Confidence Limit | 38.4 |
Readmission Rate: Lower Confidence Limit | 16 |
News Archive
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.
A research project is exploring whether interventions that have been effective at engaging high-risk populations in HIV/AIDS testing and treatment can be adapted to achieve similar effects in mitigating COVID-19.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.
› Verified 9 days ago